BofA reiterates Buy on Chewy stock, cites Modern Animal synergies By Investing.com

Chewy announced the acquisition of Modern Animal, adding >$125M in annual revenue and expanding Chewy Vet Care locations from 18 to 47; the deal is expected to be EBITDA dollar‑neutral in FY2026. Company LTM EBITDA was $341.9M with gross profit margin ~30% and mature clinic margins >20%, suggesting long‑term margin upside as vet operations scale. The Board approved a $500M increase to the share repurchase program (on top of $119.4M remaining), and multiple firms (BofA PT $40 Buy, Mizuho PT $50 Outperform, Argus PT lowered to $35 Buy) reiterated coverage; 9 analysts have revised earnings higher.

Analysis

Chewy’s move into full-service veterinary verticals is less about immediate EBITDA lift and more about creating high-LTV, recurring touchpoints that materially increase wallet share per customer over a multi-year horizon. If Chewy captures even a modest share of annualizable clinic spend per existing customer, the cross-sell of prescriptions, preventive products, and subscriptions can compound ARPU by mid-single digits annually; the lever is operating leverage in distribution and prescription margin recapture.

The main constraint that consensus underappreciates is labor and regulatory friction in scaling clinics. Veterinarian supply is tight and credentialing/medical compliance costs create a long, stepwise scale curve—meaning margin expansion is lumpy and likely to arrive in discrete phases as telehealth efficiency, centralized pharmacy, and staffing models prove out.

Strategically, this pushes Chewy into direct competition with national clinic networks and pet-insurance/payment providers, shifting bargaining dynamics for wholesale meds and clinic referrals. A successful roll-up would pressure smaller independent clinics and could force incumbents to bulk up or partner, accelerating M&A in the space and creating acquisition arbitrage opportunities for well-capitalized players.

Near-term catalysts to watch are integration metrics (same-clinic revenue retention, subscription attach rate to clinic patients, and pharmacy margin recapture) over the next 4–12 quarters; negative catalysts are rising clinic labor costs, unfavorable telemedicine regulation, or slower-than-expected cross-sell adoption that would push accretion further into the back half of the medium term.

Key Decisions for Investors

• Long CHWY equity + protective put (6–12 months): Buy CHWY shares and buy a 6–12 month out-of-the-money put (~10–15% OTM) to cap downside from integration execution risk; if cross-sell metrics accelerate, expect >2x upside over 12–24 months while limiting tail loss to the put premium.
• Call spread (event-driven, 9–18 months): Buy a 9–18 month call and sell a higher strike call (call spread) to reduce premium outlay, targeting margin-accretion proof points in next two quarters; max gain is capped but offers ~2–3x asymmetric payoff vs premium if integration KPIs inflect positively.
• Pair trade (12 months): Long CHWY / short WOOF to isolate e-commerce + veterinary platform execution vs retail/omnichannel exposure—expect relative outperformance if clinic unit economics scale and subscription ARPU rises; size as a market-neutral pair with stop if divergence reverses by >20%.
• Event hedge & monitoring: Reduce net long exposure into earnings or integration updates; use short-dated puts as insurance around quarterly releases and add on confirmed improvements in clinic retention, pharmacy margin recapture, or subscription attach — exit hedges incrementally as each KPI prints positively.